Control Bionics Ltd (CBL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Control Bionics Ltd (CBL) has a cash flow conversion efficiency ratio of -0.288x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.22 Million ≈ $-1.57 Million USD) by net assets (AU$7.73 Million ≈ $5.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Control Bionics Ltd's balance sheet to measure how much of total assets are equity-financed.
Control Bionics Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Control Bionics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore CBL operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Control Bionics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Control Bionics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Clean Seas Seafood Ltd
AU:CSS
|
0.194x |
|
Japan Gold Corp
V:JG
|
-0.051x |
|
SSP Group PLC
LSE:SSPG
|
1.962x |
|
Artmarket.com SA
PA:PRC
|
0.031x |
|
BonTerra Resources Inc
V:BTR
|
0.894x |
|
Everbright Digital Holding Limited Ordinary Shares
NASDAQ:EDHL
|
N/A |
|
Andalan Perkasa Abadi Tbk PT
JK:NASA
|
0.000x |
|
Wooyang Co. Ltd
KQ:103840
|
0.087x |
Annual Cash Flow Conversion Efficiency for Control Bionics Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Control Bionics Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see CBL stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | AU$5.51 Million ≈ $3.90 Million |
AU$-4.27 Million ≈ $-3.02 Million |
-0.775x | +1.11% |
| 2023-12-31 | AU$6.27 Million ≈ $4.43 Million |
AU$-4.91 Million ≈ $-3.48 Million |
-0.784x | -23.18% |
| 2022-12-31 | AU$7.12 Million ≈ $5.04 Million |
AU$-4.53 Million ≈ $-3.20 Million |
-0.636x | -10.15% |
| 2021-12-31 | AU$11.92 Million ≈ $8.44 Million |
AU$-6.89 Million ≈ $-4.87 Million |
-0.578x | -148.41% |
| 2020-12-31 | AU$17.16 Million ≈ $12.14 Million |
AU$-3.99 Million ≈ $-2.82 Million |
-0.233x | -441.59% |
| 2019-12-31 | AU$20.13 Million ≈ $14.24 Million |
AU$-864.05K ≈ $-611.37K |
-0.043x | +88.85% |
| 2018-12-31 | AU$5.05 Million ≈ $3.58 Million |
AU$-1.95 Million ≈ $-1.38 Million |
-0.385x | -141.49% |
| 2017-12-31 | AU$6.09 Million ≈ $4.31 Million |
AU$-970.84K ≈ $-686.93K |
-0.159x | -- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more